Page 2 - Hikal

Hikal slips 21% in one week, hits fresh 52-week low on disappointing Q4

The inflationary pressures and a sharp rise in input costs of raw material, energy and solvents, the management expects industry growth to be tapered and margins to be contract in the current fiscal.

Here's why Mehul Kothari recommends buying Hikal, Jindal Saw

According to the technical analyst from Anand Rathi, JINDALSAW has seen a strong resurgence in the last two sessions backed by robust volumes indicating soaring demand at lower levels

Here's why Subash Gangadharan is bullish on Hikal, Gujarat Gas

The technical & derivative analyst from HDFC Securities expects weakness in Nifty to continue

Hikal hits new high on signing 10-year deal with global pharma Co

This contract entails the development and supply of a portfolio of niche APIs (Active Pharmaceutical Ingredient) over a period of 10 years

Hikal's profit after tax rises 42.8% to Rs 40 crore in December quarter

Hikal on Thursday reported a 42.85 per cent rise to Rs 40 crore in consolidated profit after tax (PAT) during the quarter ended December 31, 2020.

Hikal shares advance 12%, hit 52-week high on growth prospects

For the April-June quarter (Q1FY21), Hikal reported a 25 per cent year-on-year (YoY) decline in its consolidated profit before tax (PBT) at Rs 27.50 crore.

Hikal freezes at 5% upper circuit on development of Favipiravir API

Favipiravir is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.

Hikal hits 52-week high after Ashish Kacholia buys 1.6% stake

Hikal hits 52-week high of Rs 192, up 4% on Tuesday, extending its previous day's 15% surge on the National Stock Exchange.

Hikal soars as USFDA issues 'Zero' 483 observations for Bangalore facility

The stock soared 18% to Rs 257, also its record high on the NSE in intra-day trade